Cost-effectiveness of hepatitis A vaccination in children, adolescents, and adults
- 1 January 2003
- journal article
- review article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 37 (1) , 44-51
- https://doi.org/10.1053/jhep.2003.50016
Abstract
Hepatitis A is a major public health problem in the United States and other developed countries, largely because decreased natural immunity allows for increased susceptibility. To evaluate the cost-effectiveness of routine vaccination of children, adolescents, and certain high-risk adults against hepatitis A, economic analyses of hepatitis A vaccination were identified through searches of MEDLINE, EMBASE, and BIOSIS (February, 1992, to December, 2001) for studies, reviews, editorials, and letters from peer-reviewed journals published in English, French, German, Italian, or Spanish. Experts were also contacted. Articles conforming to accepted standards of quality for health-economic studies were used to compile data on vaccination of children, and results were synthesized in a narrative review. This review of economic analyses of vaccine use in several developed countries shows cost-effectiveness comparable with that of other vaccines in children and within accepted boundaries for adolescents and high-risk adults.Keywords
This publication has 55 references indexed in Scilit:
- Recommended Childhood Immunization Schedule—United States, 2001Published by American Medical Association (AMA) ,2001
- Cost-effectiveness of Pneumococcal VaccineJAMA, 2000
- The cost of hepatitis A infections in American adolescents and adults in 1997Hepatology, 2000
- Hepatitis A shifting epidemiology in South-East Asia and ChinaVaccine, 2000
- Cost-effectiveness analysis of hepatitis A vaccination strategies for adultsHepatology, 1999
- An Economic Analysis of Different Strategies of Immunization Against Hepatitis A Virus in Developed CountriesHepatology, 1999
- Cost-Effectiveness of Hepatitis A Vaccination in Healthcare WorkersInfection Control & Hospital Epidemiology, 1997
- A Model of Long-Term Decline in the Transmissibility of an Infectious Disease: Implications for the Incidence of Hepatitis AInternational Journal of Epidemiology, 1996
- Duration of protection from clinical hepatitis A disease after vaccination with VAQTA®Journal of Medical Virology, 1996
- Inactivated hepatitis A vaccine: Reactogenicity, immunogenicity, and long‐term antibody persistenceJournal of Medical Virology, 1994